SynthesisZeitschrift fur Rheumatologie2026
Comparative efficacy and safety of denosumab biosimilar and originator in postmenopausal osteoporosis: a meta-analysis of randomized controlled trials.
Synthesis in Zeitschrift fur Rheumatologie, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Efficacy and safety of denosumab biosimilars in the treatment of postmenopausal osteoporosis: A systematic review of randomized clinical trials.Clinical and experimental medicine · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe study aimed to assess whether a denosumab biosimilar is as effective and safe as the original denosumab for treating postmenopausal osteoporosis.
methodsA comprehensive search of MEDLINE, Embase, and the Cochrane databases identified six randomized controlled trials (RCTs) relevant to this study. The meta-analysis focused on evaluating percentage changes in bone mineral density (BMD) at the lumbar spine, femoral neck, and total hip, alongside monitoring adverse events (AEs), serious adverse events (SAEs), and infections.
resultsThe analysis encompassed 1784 patients, with 978 and 816 receiving biosimilar and originator therapy, respectively. Regarding standardized mean differences (SMDs) for BMD changes, a lumbar spine SMD of -0.048 (95% confidence interval [CI]: -0.142 to 0.046; P = 0.317), femoral neck SMD of 0.089 (95% CI: -0.068 to 0.247; P = 0.266), and total hip SMD of 0.029 (95% CI: -0.153 to 0.212; P = 0.755) were found, showing no significant differences between the two treatments. Safety profiles were also comparable, with odds ratios (ORs) of 1.168 (95% CI: 0.795-1.716; P = 0.428) for AEs, 1.120 (95% CI: 0.644-1.946; P = 0.689) for SAEs, and 1.576 (95% CI: 0.657-3.780; P = 0.308) for infections.
conclusionThe denosumab biosimilars demonstrated efficacy and safety profiles comparable to the originator in the treatment of postmenopausal osteoporosis.
Indexed as
Identifiers
40993439What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.